Generic Portal

Adaptive Radiotherapy:
Together with the NKI the AMC RT department will start ART for cervix cancers.
Topics:
• Pathological validation of MR imaging of surgical specimen, together with dept of gynecology, Radiology and Pathology (G. Kenter, J. Stoker, A. Nederveen and M. van de Vijver) (AGIKO-RT, AMC).
• Quantification of Cervix and Uterus motion during RT course for cervix and endometrial cancer together with NKI (M. Bloemers, NKI)
• ART strategies for Cervix cancer, dose summation in the prospect of adaptive RT, the deformable registration tools developed for head and neck cancer and bladder cancer will be used for the prediction of the Uterus position and summation of the dose to the organs at risk (OIO, AMC).
• Regional treatment results Cervix cancer (R. Davila Fajardo, AMC). Based upon retrospective data patterns of recurrence for the lymphnodes in cervix cancer will be analyzed. Together with the developments in ART for the Cervix strategies for improving the regional control will be developed.

Multimodality treatment
• Within ARTFORCE a clinical phase II dose escalation trial for lung cancer is started. The AMC will take part in this trial after accreditation by ARTFORCE.
• Within the AMC gastro-intestinal cancer is an important issue. In cooperation with MAASTRO and within the partners of ARTFORCE visualization of hypoxia with HX4 and TH-302 for esophageal cancer is intended depending on approval of medical ethical committee and consensus within GIOCA group at AMC.
• Adaptive RT for esophageal cancer and pancreas with on-line treatment planning will be developed (OIO, AMC).
• A KWF grant proposal for support for clinical trials on the ARTFORCE project is pending after resubmission in October 2011 (initial R-rating)